Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Hospitalization 67% Improvement Relative Risk Progression 19% Progression (b) 6% primary c19aspirin.com Connors et al. NCT04498273 Aspirin RCT EARLY TREATMENT Favors aspirin Favors control
Connors, 280 patient aspirin early treatment RCT: 67% lower hospitalization [p=0.49] and 19% lower progression [p=0.78] https://c19p.org/connors
copied to clipboard
Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients With Clinically Stable Symptomatic COVID-19
11 Oct 2021    Source   PDF   Share   Tweet
Early terminated RCT with 164 aspirin and 164 control patients in the USA with very few events, showing no significant difference with aspirin treatment for the combined endpoint of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, and hospitalization for cardiovascular or pulmonary indication. There was no mortality and no major bleeding events among participants that started treatment (there was one ITT placebo death). ACTIV-4B. NCT04498273 (history).
risk of hospitalization, 67.3% lower, RR 0.33, p = 0.49, treatment 0 of 144 (0.0%), control 1 of 136 (0.7%), NNT 136, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), hospitalization for cardiovascular or pulmonary indication, suspected, started treatment.
risk of progression, 19.0% lower, RR 0.81, p = 0.78, treatment 6 of 144 (4.2%), control 7 of 136 (5.1%), NNT 102, acute medical event, suspected, started treatment.
risk of progression, 5.6% lower, RR 0.94, p = 1.00, treatment 1 of 144 (0.7%), control 1 of 136 (0.7%), NNT 2448, combined endpoint of all-cause mortality, symptomatic venous or arterial thromboembolism, myocardial infarction, stroke, and hospitalization for cardiovascular or pulmonary indication, suspected, started treatment, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Connors et al., 11 Oct 2021, Double Blind Randomized Controlled Trial, placebo-controlled, USA, peer-reviewed, 27 authors, trial NCT04498273 (history).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit